Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
| Revenue (TTM) | $2.91B |
| Gross Profit (TTM) | $1.89B |
| EBITDA | $-187.94M |
| Operating Margin | -8.61% |
| Return on Equity | -10.50% |
| Return on Assets | -7.12% |
| Revenue/Share (TTM) | $20.51 |
| Book Value | $12.95 |
| Price-to-Book | 30.94 |
| Price-to-Sales (TTM) | 18.03 |
| EV/Revenue | 20.51 |
| EV/EBITDA | -26.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.10% |
| Shares Outstanding | $144.14M |
| Float | $140.97M |
| % Insiders | 2.72% |
| % Institutions | 96.54% |
Volatility is currently expanding
Natera NASDAQ: NTRA raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in leadership.
The Alger Concentrated Equity ETF underperformed the Russell 1000 Growth Index during the third quarter of 2026. Microsoft Corporation, Natera, Inc., and Meta Platforms Inc were among the top contributors to performance. Western Digital Corporation, QXO, Inc., and Nebius Group were among the top detractors from performance.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026. Recent Financial Highlights Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. Generated a gross margin1 of 64.7% in the third quarter of 2026, compared to a gross margin1 of 64.9% in the third q.
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology holdings and underweight to the Energy sector detracted from returns. For the year-to-date period, the Fund returned 5.80% (net of fees), outperforming the Russell Midcap Growth Index's 1.01%.
Class A shares of the Alger Dynamic Opportunities Fund underperformed the S&P 500 Index during the third quarter of 2026. During the quarter, long positions, in aggregate, detracted from both absolute and relative performance. Short positions, in aggregate, contributed to both absolute and relative performance.
Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera's technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications. Results from the phase III VOLGA trial in muscle-invasive bladder canc.
Druckenmiller owns a large stake in Natera. The company is growing quickly by disrupting the healthcare testing market.
NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NTRA and any ticker you trade — then tracks every position and per-strategy win rate.
